Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.70 |
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | CA9 | Q16790 | 5/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.70 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.56 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530297 | 0.83 | CNR2 (0.68) | CA1CA2CA12CA9CA14 | |
| SCHEMBL6799582 | 0.81 | STS (0.63) | CA1CA2CA12CA9CA14 | |
| SCHEMBL13296366 | 0.81 | HTT (0.65) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22230464 | 0.81 | HTT (0.65) | CA1CA2CA12CA9CA14 | |
| SCHEMBL8413524 | 0.81 | HTT (0.65) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3291832 | 0.81 | HTT (0.65) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14380627 | 0.80 | CYP19A1 (0.57) | CA1CA2CA12CA14HTT | |
| SCHEMBL3716044 | 0.79 | HTT (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL13296361 | 0.79 | HTT (0.76) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22350942 | 0.79 | HTT (0.61) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-109071473-B | Antiviral compounds | 创新分子股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| CN-109071473-A | Novel antivirus compound | 创新分子股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1489069-A2 | Preparation of sulfonyl imine compounds | E.I. du Pont de Nemours and Company (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1216227-B1 | PREPARATION OF SULFONYL IMINE COMPOUNDS | DU PONT (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2001023352-A9 | PREPARATION OF SULFONYL IMINE COMPOUNDS | DU PONT (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-1216227-A2 | PREPARATION OF SULFONYL IMINE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6380429-B1 | OXIDATION OF SULFONAMIDE | E. I. DU PONT NEMOURS AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| WO-2001023352-A2 | PREPARATION OF SULFONYL IMINE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CA1 4607/4885CA2 4701/4885CA12 4825/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CA1 4607/4885CA2 4701/4885CA12 4825/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CA1 4607/4885CA2 4701/4885CA12 4825/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CA1 4607/4885CA2 4701/4885CA12 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.